Skip to main content
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics — Investor Relations & Filings

Ticker · MLTX ISIN · KY61559X1045 US Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2021-11-24 Regulatory Filings
Country US United States of America
Listing US MLTX

About MoonLake Immunotherapeutics

https://moonlaketx.com/

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immunologic diseases by leveraging Nanobody® technology. The company's lead investigational asset is sonelokimab, a Nanobody designed to target key inflammatory pathways. MoonLake is advancing sonelokimab through late-stage clinical development, with Phase 3 programs (VELA and IZAR) underway for the treatment of hidradenitis suppurativa (HS) and psoriatic arthritis (PsA). The company focuses on addressing conditions with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-11-24 English
Regulatory Filings 2021
Regulatory Filings
2021-11-24 English
SCHEDULE13G/A
Major Shareholding Notification
2021-11-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2021
2021-11-12 English
PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed under Schedule 14A with the SEC, as indicated by the header and the title 'PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION, DATED OCTOBER 29, 2021.' It relates to an extraordinary general meeting of shareholders of Helix Acquisition Corp. to vote on a Business Combination Agreement and related matters. The content includes detailed information about the business combination, share structure changes, voting procedures, and shareholder meeting logistics. Proxy Statements are materials sent to shareholders to provide information and request votes for meetings, matching the definition of Proxy Solicitation & Information Statement (PSI). The document is lengthy (15,000 characters) and contains substantive information typical of a proxy statement, not just an announcement or a brief notice. Therefore, the correct classification is PSI with high confidence.
2021-10-29 English
ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIAL
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIAL' and references Schedule 14A, which is a proxy statement filing pursuant to Section 14(a) of the Securities Exchange Act of 1934. It discusses solicitation of proxies related to a business combination between Helix Acquisition Corp. and MoonLake Immunotherapeutics AG. The text includes cautionary statements about forward-looking information, instructions on where to find the definitive proxy statement when filed, and details about participants in the solicitation. It explicitly states that this communication is not a proxy statement itself but additional soliciting material. There is no financial data or report content, only solicitation materials related to a proxy vote. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2021-10-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.